Navigation Links
CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients

Proposed Medicare Ruling Would End Pulmonary Rehab for Thousands of Dying Patients

SAN JOSE, Calif., Aug. 31 /PRNewswire-USNewswire/ -- Today, pulmonary fibrosis (PF) patient Ellen Foley went to the pulmonary rehabilitation (rehab) program near her home in Middlesex, N.C. At the same time, the Coalition for Pulmonary Fibrosis (CPF) took a stand for her and thousands of patients like her. Soon, Foley may not be able to go to therapy if the Centers for Medicare and Medicaid Services (CMS) are successful in pushing forward a proposed ruling regarding pulmonary rehabilitation coverage that would limit coverage and eliminate patients with diseases like Foley's. PF has no treatments and no cure and is a disease that scars the lungs and suffocates its victims. It is almost invariably fatal. Most patients live less than three years and the only affective therapy to help them is pulmonary rehab.

The CMS proposed ruling states "because there is not data to substantiate significantly improved outcomes for any other medical conditions, we are proposing to allow moderate to severe COPD as the only covered condition." There is, in fact, substantial evidence that there is significant benefit to PF patients and patients with other respiratory diseases.

The proposed ruling can be viewed at and is file code CMS-1413-P. The docket title is "Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2010."

With patients, like Foley, in mind, the CPF submitted comments to combat the CMS proposal. "This is a case study in the challenges representative of patients fighting rare diseases like PF. Namely, that healthcare coverage for those with rare diseases like PF is materially and negatively impacted largely due to the size of its patient population, a lack of awareness of the benefits of cardiac and pulmonary rehabilitation on these patients, and, frankly, the increased attention typically afforded diseases of higher prevalence, such as COPD, in Federal programs," the CPF included in its comments.

"I need my pulmonary rehab program," said patient Ellen Foley who has less than 50 percent lung capacity remaining. "It has helped me breathe better and helps me try to stay ahead of my disease. Even though I know my PF is getting worse, by going to pulmonary rehab, I can make the most of the lung function I have left."

Even though Congress passed a national coverage policy for pulmonary rehab earlier this year that was designed to include patients with PF and other lethal or chronic lung diseases, CMS threatens to prevent them from receiving the benefit that Congress worked to provide. Patients and experts worry that private insurance payers will follow suit and no coverage for pulmonary rehab will be available for the majority of patients who suffer from deadly lung diseases like PF. The only disease CMS plans to cover, under the proposed ruling, would be Chronic Obstructive Pulmonary Disease (COPD); and even COPD is being negatively affected by the ruling that plans to limit its coverage to basically only end stage patients.

"We are stunned that CMS would propose such a sweeping and negatively impacting ruling that harms so many patients. We hope that they will thoroughly review our comments and the more than 2,000 that have been submitted to them by concerned medical professionals and patient groups nationwide," said Mishka Michon, Chief Executive Officer of the CPF. "Then, it is hope that CMS will reconsider its position and provide coverage for the many types of patients who need and deserve it."

The CPF also joined with those of other patient groups as part of the American Thoracic Society's (ATS) Public Advisory Roundtable (PAR) to make collective comment.

PF patients are referred by their physicians to pulmonary rehab for medically supervised exercise and therapy designed to preserve some of their lung capacity, help their bodies avoid infections and sustain or improve, for as long as possible, their quality of life.

CMS accepts public comment on the proposed ruling until midnight tonight.

Top pulmonologists and PF experts joined the CPF in making its comments to CMS. They are:

  • Marvin Schwarz, MD, James C. Campbell Professor of Medicine University of Colorado Health Sciences Center and the CPF's board of directors chairman
  • James Loyd, MD, Medical Co-Director, Lung Transplant Program Medical Co-Director, FLOLAN Program for Primary Pulmonary Hypertension, Vanderbilt University Medical Center
  • Adaani Frost, MD, Professor of Medicine, Baylor College of Medicine
  • Paul Noble, MD, Professor of Medicine Division Chief, Allergy & Critical Care Medicine, Duke University Medical Center and the CPF's chairman of its scientific advisory board
  • Glenn Rosen, MD, Associate Professor of Medicine, Division of Pulmonary & Critical Care Co-Director, Stanford University Lung Disease Center, Stanford Medical Center
  • Marilyn Glassberg, MD, Assistant Professor of Medicine, Division of Pulmonary & Critical Care Medicine, University of Miami/Jackson Memorial Medical Center
  • Jeffrey Golden, MD, Medical Director, Lung Transplantation Director, Interstitial Lung Disease Clinic University of California, San Francisco
  • Harold Collard, MD, University of California, San Francisco
  • Stephen Nathan, MD, Medical Director, Lung Transplant & Advanced Lung Disease Programs, Inova Fairfax Hospital
  • Maria Padilla, MD, Associate Professor of Medicine Director of the Advanced Lung Disease Program, Mt. Sinai Medical Center
  • Ganesh Raghu, MD, Professor of Medicine, University of Washington, Chief of Chest Clinic
  • Director, Lung Transplant Program and Interstitial Lung Disease Program University of Washington Medical Center
  • Fernando Martinez, MD, Associate Professor, Division of Pulmonary and Critical Care Medicine Director, Lung Volume Reduction Program, Medical Director, Pulmonary Diagnostic Services University of Michigan Medical Center

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 19,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit or call (888) 222-8541.

SOURCE Coalition for Pulmonary Fibrosis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm submits response to FDA for novel antidepressant
2. MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production
3. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
4. Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product
5. Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
6. DxNA Submits its Rapid Detection Platform Test for H1N1 to FDA
7. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
8. USCCB Submits Comments to NIH on Proposed Guidelines for Stem Cell Research
9. GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
10. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
11. Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
Post Your Comments:
(Date:9/22/2017)... ... , ... On Sunday, September 24, hundreds will gather at Flo Jo Park ... the fastest woman of all time. Flo Jo passed away from complications related ... National Anthem. Mary was a contestant on the 2012 season of America’s Got ...
(Date:9/22/2017)... ... September 22, 2017 , ... Fenwick Agency of Plano, TX has announced the ... part of the nationally recognized ‘Agents of Change’ movement. The agency pledges to select ... leaders to seek out those who most need help. Their hope is to bring ...
(Date:9/22/2017)... ... September 22, 2017 , ... After ... a senior finds a new lease on life with assistance from CreditAssociates. CreditAssociates ... resolve their problem with unsecured debt. The senior is one of the satisfied ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from ... in Educational Leadership and Administration at St. Thomas University in Miami, Florida, was ...
(Date:9/22/2017)... IL (PRWEB) , ... September 22, 2017 , ... Pullano ... attorney Richard L. Pullano has been selected to serve as President of ... 50th President at the Installation and Award Dinner hosted by the NSBA at the ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the latest ... Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... include new preclinical and clinical data on Bayer,s marketed portfolio ... pipeline projects. "We ... minds in cancer research at ESMO," said Carsten Brunn ...
Breaking Medicine Technology: